Skip to main content
Premium Trial:

Request an Annual Quote

Lantern Pharma, TTC Oncology Ink Biomarker Discovery, Licensing Deal for Breast Cancer Drug

NEW YORK – Lantern Pharma and TTC Oncology said on Monday that they began a research and development collaboration focused on TTC's estrogen receptor (ER) agonist TTC-352.

Lantern will use its artificial intelligence platform, RADR, and machine-learning platform to identify biomarker signatures to select patients for treatment with TTC-352, further characterize the drug's mechanism of action, and identify more treatment indications for TTC-352. The RADR platform uses data from clinical trials, public databases, and models of drug-tumor interactions to identify biomarkers of activity.

TTC is studying its lead candidate in recurrent ER+ breast cancer patients in a Phase I study and hopes the collaboration with Lantern will identify potential biomarkers for treatment benefit to select patients for its upcoming Phase II trial. The firm had previously identified that PKCa overexpression was associated with benefit from TTC-352.

"It is of the utmost importance for cancer drug development to understand targeted tumor biology and mechanisms of resistance in order to select the patient population that will benefit the most from novel therapy," TTC Chief Medical Officer Arkadiusz Dudek said in a statement. "We expect that by using Lantern's RADR AI platform it can save us time and costs in the further successful clinical development of TTC-352 while providing important information for precision patient selection."

Under the collaboration, Lantern Pharma will receive exclusive rights to license TTC-352 and any collaboration-related intellectual property during an option period. If a third party licenses the drug, both Lantern and TTC will participate in upfront, milestone, and royalty payments. Other financial details about the collaboration were not disclosed.